The CRISPR-Cas9 Intellectual Property

ERS Genomics holds an exclusive worldwide license from Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 for all applications other than use as a human therapeutic. This patent application has broad and dominant claims covering CRISPR-Cas9 compositions and methods of genome editing in any organism.

Companies may obtain licenses to this foundational intellectual property for internal research and commercialization of research tools, kits, reagents, and genetically modified cell lines and organisms.

 

The Patent Filing

The patent application entitled “Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of Transcription” was filed on March 15, 2013 and has the designation PCT/US2013/032589. Here is a link to the PCT filing.  

Named on the patent application as inventors and where they worked at the time were:

  • Emmanuelle Charpentier – University of Umeå (Sweden)
  • Krzysztof Chylinski – University of Vienna (Austria)
  • Jennifer Doudna – University of California (USA)
  • Martin Jinek – University of California (USA)
  • James Harrison Doudna-Cate- University of California (USA)
  • Wendell Lim – University of California (USA)
  • Lei Qi – University of California (USA)

Under Swedish law Emmanuelle Charpentier was allowed to retain her personal rights and ownership in the patent. All of the other inventors were obligated to assign their rights to their universities. This gave rise to three ownership groups:

  • Emmanuelle Charpentier
  • The Regents of the University of California
  • The University of Vienna

Emmanuelle Charpentier exclusively licensed her rights to two new companies:

  • CRISPR Therapeutics – rights to use the technology to treat human disease
  • ERS Genomics – all rights except use of the technology to treat human disease

The two universities together gave an exclusive license in their rights to:

  • Caribou BioSciences. Caribou subsequently established Intellia Therapeutics and gave them rights to most human healthcare applications.

The patent application has been filed in over 60 countries worldwide. The map below depicts the geographical area in which the patent application has been filed.

Patents are being actively prosecuted in all of the above countries, but granted claims have issued so far in:

Country
Patent No.
Grant Date

Australia

Australia

China

Europe

Europe

Europe

United Kingdom

AU 2013266968 B2

AU 2017225060 B2

CN 104854241 B

EP 2800811 B1

EP 3241902 B1

EP 3401400 B1

GB 2518764 C

07 Dec 2017

02 May 2019

14 Jul 2017

10 May 2017

28 Feb 2018

03 Apr 2019

02 Mar 2016

United Kingdom

Hong Kong

Hong Kong

Hong Kong

Israel

Japan

Mexico

Mexico

New Zealand

Singapore

Singapore

Tunisia

Ukraine

United States

United States

United States

United States

United States

United States

United States

United States

United States

United States

South Africa

Germany

GB 2537000 B

HK 1207107 B

HK 1211978 B

HK 1230233 B

IL 235461

JP 6343605 B

MX 349744 B

MX 362866 B

NZ 714353 B2

SG 10201701800Y

SG 11201407702X

TN 24223

UA 118014

US 10000772 B2

US 10113167 B2

US 10227611 B2

US 10266850 B2

US 10301651 B2

US 10308961 B2

US 10337029 B2

US 10351878 B2

US 10358658 B2

US 10358659 B2

ZA 2014/07881

DE 202013012240 U1

08 Mar 2017

25 Aug 2017

04 May 2018

01 Jun 2018

01 May 2019

25 May 2018

10 Aug 2017

20 Feb 2019

29 Aug 2017

21 Nov 2018

20 Mar 2017

03 Jun 2016

12 Nov 2018

19 Jun 2018

30 Oct 2018

12 Mar 2019

23 Apr 2019

28 May 2019

04 Jun 2019

02 Jul 2019

16 Jul 2019

23 Jul 2019

23 Jul 2019

31 Jan 2018

02 Feb 2016

Germany

DE 202013012241 U1

18 Jan 2016

Germany

DE 202013012242 U1

02 Feb 2016